MAIA Biotechnology (MAIA) announced the publication of preclinical data for its lead proprietary telomere-targeting THIO dimer in the ...

THIO has gained its generic name and preclinical data on a different form of the cancer drug suggests it could improve ...

MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug ...

MAIA Biotechnology is an immuno-oncology company specializing in targeted therapies aimed at enhancing the treatment of cancer. Its primary candidate, THIO, is a novel drug in clinical trials ...

MAIA Biotechnology, Inc., (NYSE American ... name for its lead molecule THIO, a telomere-targeting anticancer agent in clinical development as a first-in-class treatment for advanced non-small ...

(RTTNews) - MAIA Biotechnology Inc. (MAIA), on Wednesday ... nonproprietary name for its investigational anticancer agent, THIO. The approval is an important step in the regulatory process ...

About Ateganosine Ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine ... regimen of existing checkpoint inhibitors. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology ...

MAIA Biotechnology Receives USAN Council Approval for "Ateganosine" as Nonproprietary Name for Anticancer Agent THIO ...